ProCE Banner Activity

Phase II CAPTIVATE Trial of First-line Ibrutinib Plus Venetoclax in CLL/SLL: MRD Cohort Results

Slideset Download
Conference Coverage
Initial results from the phase II CAPTIVATE trial demonstrated that ibrutinib plus venetoclax yielded high rates of undetectable MRD in patients with previously untreated CLL/SLL.

Released: December 11, 2019

Expiration: December 09, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company